Infarktbedingter kardiogener Schock: Revaskularisation, mechanische Unterstützung und medikamentöse Therapie

Schlüsselwörter

kardiogener Schock - medikamentöse Therapie - Revaskularisation - mechanische Unterstützung

Keywords

cardiogenic shock - pharmacotherapy - revascularization - mechanical support

Literatur

• 1 Anderson R D, Ohman E M, Holme Jr D R, Col J, Stebbins A L, Bates E R. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study.  J Amer Coll Cardiol. 1997;  30 708-715
• 2 Babaev A, Frederick P D, Pasta D J, Every N, Sichrovsky T, Hochman J S. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.  JAMA. 2005;  294 448-454
• 3 Brookes C, Ravn H, White P, Moeldrup U, Oldershaw P, Redington A. Acute right ventricular dilatation in response to ischemia significantly impairs left ventricular systolic performance.  Circulation. 1999;  100 761-767
• 4 Burkhoff D, Cohen H, Brunckhorst C, O’Neill W W. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.  Am Heart J. 2006;  152 469 e1-e8
• 5 Cassidy S S, Mitchell J H. Effects of positive pressure breathing on right and left ventricular preload and afterload.  Fed Proc. 1981;  40 2178-2181
• 6 Chen E W, Canto J G, Parsons L S. et al . Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock.  Circulation. 2003;  108 951-957
• 7 Christoph A, Prondzinsky R, Russ M, Janusch M, Schlitt A, Lemm H, Reith S, Werdan K, Buerke M. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction.  Acute Cardiol Care. 2008;  10 49-57
• 8 Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, Krakover R, Golick A, Vered Z. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock.  Eur Heart J. 2003;  24 1287-1295
• 9 Cotter G, Williams S G, Vered Z, Tan L B. Role of cardiac power in heart failure.  Curr Opin Cardiol. 2003;  18 215-222
• 10 Cuffe M S, Califf R M, Adams K F Jr. et al . Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.  JAMA. 2002;  287 1541-1547
• 11 Delle Karth G, Buberl A, Geppert A. et al . Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.  Acta Anaesthesiol Scand. 2003;  47 1251-1256
• 12 Fincke R, Hochman J S, Lowe A M, Menon V, Slater J N, Webb J G, LeJemtel T H, Cotter G. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry.  J Am Coll Cardiol. 2004;  44 340-348
• 13 Friedrich J O, Adhikari N, Herridge M S, Beyene J. Low-dose dopamine increases urine output but does not prevent renal dysfunction or death.  Ann Intern Med. 2005;  142 510-524
• 14 Granger C B, Mahaffey K W, Weaver W D. et al . Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.  Circulation. 2003;  108 1184-1190
• 15 Hochman J S, Sleeper L A, Webb J G, Dzavik V, Buller C E, Aylward P, Col J, White H D. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.  JAMA. 2006;  295 2511-2515
• 16 Hochman J S, Sleeper L A, Webb J G. et al . Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.  N Engl J Med. 1999;  341 625-634
• 17 Hochman J S, Boland J, Sleeper L A. et al . Current spectrum of cardiogenic shock and effect of early revascularization on mortality: Results of an International Registry.  Circulation. 1995;  91 873-881
• 18 Jacobs A K, Leopold J A, Bates E. et al . Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry.  J Am Coll Cardiol. 2003;  41 1273-n
• 19 Jolly S, Newton G, Horlick E. et al . Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction.  Amer J Cardiol. 2005;  96 1617-1620
• 20 Klein L W, Shaw R E, Krone R J. et al . Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model.  Am J Cardiol. 2005;  96 35-41
• 21 Koreny M, Geppert A, Wutte M, Karth G D, Heinz G, Siostrzonek P. Effects of milrinone on pulmonary gas exchange in catecholamine-dependent heart failure.  Amer J Cardiol. 2000;  86 570-573
• 22 Montalescot G, Barragan P, Wittenberg O. et al, for the ADMIRAL Investigators . Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med. 2001;  344 1895-1903
• 23 Ohman E M, Nanas J, Stomel R J. et al . Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial.  J Thromb Thrombolysis. 2005;  19 33-39
• 24 Picard M H, Davidoff R, Sleeper L A, Mendes L A, Thompson C R, Dzavik V, Steingart R, Gin K, White H D, Hochman J S. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.  Circulation. 2003;  107 279-284
• 25 Ramanathan K. Harkness S M. Nayar A C. Cosmi J E. Sleeper L S. White H D. Davidoff R. Hochman J S. Cardiogenic shock in patients with preserved left ventricular systolic function: characteristics and insight into mechanisms.  Circulation. 2004;  43 241A
• 26 Russ M A, Prondzinsky R, Christoph A. et al . Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.  Crit Care Med. 2007;  35 2732-2739
• 27 Sanborn T A, Sleeper L A, Webb J G. et al . Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial.  J Am Coll Cardiol. 2003;  42 1373-1379
• 28 Steg P G, Bonnefoy E, Chabaud S, Lapostolle F, Dubien P Y, Cristofini P, Leizorovicz A, Touboul P. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.  Circulation. 2003;  108 2851-2856
• 29 Tayara W, Starling R C, Yamani M H, Wazni O, Jubran F, Smedira N. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment.  J Heart Lung Transplant. 2006;  25 504-509
• 30 Theroux P, Armstrong P W, Mahaffey K W. et al . Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.  Eur Heart J. 2005;  26 1964-1970
• 31 Thiele H, Sick P, Boudriot E, Diederich K W, Hambrecht R, Niebauer J, Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock.  Eur Heart J. 2005;  26 1276-1283
• 32 Urban P M, Freedman R J, Ohman E M, Stone G W, Christenson J T, Cohen M, Miller M F, Joseph D L, Bynum D Z, Ferguson III J J. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation.  Am J Cardiol. 2004;  94 181-185
• 33 Valente S, Lazzeri C, Vecchio S, Giglioli C, Margheri M, Bernardo P, Comeglio M, Chiocchini S, Gensini G F. Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock.  Int J Cardiol. 2007;  114 176-182
• 34 Yehudai L, Reynolds H R, Schwarz S A, Harkness S M, Picard M H, Davidoff R, Hochman J S. Serial echocardiograms in patients with cardiogenic shock: analysis of the SHOCK Trial.  J Am Coll Cardiol. 2006;  47 (suppl A) 111A
• 35 Zeymer U, Vogt A, Zahn R, Weber M A, Tebbe U, Gottwik M, Bonzel T, Senges J, Neuhaus K L. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI): results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK).  Eur Heart J. 2004;  25 322-328
• 36 Zion M M, Balkin J, Rosenmann D, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. SPRINT Study Group.  Chest. 1990;  98 1331-5